Assessment of ocular toxicity of CDK inhibitors

This case study outlines how OFF-X™ can be leveraged to assess the potential risk of ocular toxicity associated with Cyclin-dependent kinase (CDK) inhibitors.

The recent findings of eye disorders reported during clinical studies with different CDK inhibitors leading to clinical holds 1,2 have raised various questions:

  • Is ocular toxicity a class effect of CDK inhibitors?
  • Have ocular disorders been reported with already marketed CDK inhibitors?
  • Were these toxicities anticipated in preclinical studies performed with different CDK inhibitors?
  • Is the inhibition of all CDK subtypes associated with this safety liability or does evidence suggest a particular member(s) of the family to be the culprit?

Download the case study to find out how OFF-X™ can help answer these questions.